AstraZeneca downgraded by leading investment bank. Here's why

Deutsche Bank downgraded AstraZeneca PLC from Hold to Sell, reducing its price target to £105 from £110, citing concerns over a fading post-pandemic oncology pipeline, impending patent expiries for key drugs like Farxiga in H1 2026, and skepticism regarding the efficacy of its experimental breast cancer treatment, camizestrant. The investment bank believes the shares, currently trading at 12,548p, are poised for downward pressure as the company's near-term growth drivers diminish and pipeline prospects face increased scrutiny.

Analysis

Deutsche Bank has issued a significant downgrade for AstraZeneca PLC (AZN), moving its rating from Hold to Sell and trimming the price target to £105 from £110, a notable reduction from the current 12,548p share price. This "explicitly negative" stance has already seen AZN shares decline by 1%, reflecting immediate market concern and a strongly negative sentiment.

The downgrade is primarily driven by concerns over AstraZeneca's oncology pipeline, which Deutsche Bank believes is experiencing a fading "golden run." A key factor is the impending patent expiry of the diabetes drug Farxiga in the first half of 2026, which will likely impact future revenue streams. Furthermore, the bank expresses skepticism regarding the efficacy of camizestrant, an experimental breast cancer treatment, suggesting it may not offer a "meaningful benefit over current standard of care."

Despite trading at 17 times expected 2026 earnings, which is around its decade-long average, Deutsche Bank anticipates "real pressure ahead" for AstraZeneca. This revised outlook suggests that the shares, currently at the top of their recent trading range, are more likely to experience a downward drift than an upward trajectory, aligning with the bearish tone and significant market impact score of 0.7.

Key Decisions for Investors

• Investors should carefully re-evaluate their positions in AstraZeneca given Deutsche Bank's significant downgrade and bearish outlook.
• Closely monitor the progress of key pipeline assets and the impact of upcoming patent expiries, particularly for Farxiga in H1 2026.
• Consider the potential for further share price depreciation as highlighted by the revised £105 price target and the skepticism surrounding camizestrant's efficacy.